Pharma companies at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
30 pharma companies are at ASH 2026 — 4 presentations on the program and 28 with a booth in the exhibit hall. Most represented: AstraZeneca (1 on the program), Novartis (1 on the program), Regeneron (1 on the program). 28 of them have their own page in this guide. As of Sep 27, 2026.
Topic
Top represented
Showing 1–7 of 30 organizations
| Organization | ASH 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global biopharmaceutical company; hematology medicines include the BTK inhibitor acalabrutinib for CLL and mantle cell lymphoma. | Booth Exhibiting at Booth 1339 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company with hematology medicines spanning CML, immune thrombocytopenia, myelofibrosis and CAR T-cell therapy. | Booth Exhibiting at Booth 2339 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00am–10:00am B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice Newer B-cell-targeting treatments for immune thrombocytopenia and how to fit them into care to achieve lasting platelet responses. Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Symposium Fri Dec 11 3:00pm–6:00pm Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum Getting relapsed lymphoma patients to CAR-T sooner, with earlier referral, bridging therapy, sequencing choices, and management of immune and nerve toxicities. |
Regeneron Tarrytown, NY | |
Biotechnology company developing antibody medicines, including bispecific antibodies for multiple myeloma and non-Hodgkin lymphoma. | Booth Exhibiting at Booth 1229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Session T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics Memory T cells that stay put in tissues drive chronic inflammation after infection, in tumors, and after transplant, and the pathways keeping them alive. |
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company; its rare disease unit develops treatments for hemophilia and other rare blood disorders, including sickle cell disease. | Booth Exhibiting at Booth 913 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. |
Pfizer New York, NY | |
Global pharmaceutical company whose hematology portfolio spans myeloma, leukemia and hemophilia medicines. | Booth Exhibiting at Booth 2039 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Bristol Myers Squibb Princeton, NJ | |
Global biopharmaceutical company with hematology medicines in myeloma, lymphoma, leukemia and anemia, including CAR T-cell therapies. | Booth Exhibiting at Booth 1313 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading. Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. |
Sanofi Paris, France | |
Global healthcare company developing medicines and vaccines, with teams in around 100 countries. | Booth Exhibiting at Booth 2939 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Hemophilia at the Crossroads: New Evidence for Individualized Care Tailoring hemophilia prevention with factor replacement, factor-mimicking drugs, rebalancing agents, and gene therapy to protect joints and ease treatment burden. Symposium Fri Dec 11 3:00pm–6:00pm ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care Personalizing immune thrombocytopenia care beyond platelet counts, weighing new therapies alongside fatigue, cognition, heavy periods, and quality of life. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence Tailoring four-drug frontline regimens for newly diagnosed myeloma using residual disease testing, transplant criteria, and new ways of giving treatment. Symposium Fri Dec 11 11:00am–2:00pm Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice Newly diagnosed multiple myeloma care in community clinics, using frailty assessment, dose adjustment to protect quality of life, and new drug formulations. |
Instantly find 20 buyers from pharma companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction